Answers are grounded in this paper and cite their sources.
Parkinson's disease (PD) is a progressive neurodegenerative disorder, which is principally characterised by the loss of nigrostriatal dopaminergic neurons, but whose clinical and biological phenotype goes beyond dopamine deficiency. Motor features such as bradykinesia, rigidity, resting tremor and postural instability are accompanied by a wide range of non-motor features—such as cognition, mood, sleep, autonomic function, gastrointestinal function and pain. A multidimensional approach, which involves pharmacological, device-aided and rehabilitative treatments, is currently required for the treatment. Levodopa is the most effective motor disability (symptomatic) therapy but wearing off and dyskinesia occur often with long-term use. Dopamine agonists and MOA-B, COMT inhibitors, amantadine and adenosine A2A antagonism are complementary treatments, and newer delivery systems should aim to overcome pharmacokinetic issues and minimize fluctuations. Several new treatments are available to help treat advanced disease, such as continuous subcutaneous levodopa/carbidopa infusion, inhaled levodopa, and sublingual or injectable apomorphine. Recently, more interest has been generated in extended-release oral levodopa and selective dopamine D1/D5 receptor agonism, which are both now in late-stage development. Although much research has been conducted, there is no pharmacological therapy that has been conclusively proven to have disease modifying effects. New therapies are being developed to address some of the other mechanisms associated with the disease, such as aggregation and propagation of α-synuclein, dysfunction of glucocerebrosidase (GBA) and the lysosomes, leucine-rich repeat kinase 2 (LRRK2), neuroinflammation, and mitochondrial dysfunction and cellular metabolism. From a clinical perspective, the results have often been less convincing than from the preclinical studies. Several of the repurposed agents and GLP-1 receptor agonist and α-synuclein antibodies are examples of the challenges associated with moving mechanistic hypotheses into clinically meaningful slowing of progression. However, recent lixisenatide, ambroxol, ursodeoxycholic acid, LRRK2 inhibitors and prasenezumab trials have added valuable insights both in the biology and methodology of the field. The future of therapeutic development could be moving from treating the symptoms of a disease to modifying it, via the use of biomarker-driven and genetically defined trials. This review analyzes existing pharmacotherapies, novel delivery systems, and future pharmacologic options for improvement with a critical review of comparative efficacy, unmet challenges, unanswered controversies and priorities for continued research and development.
No takes yet. Share an insight, caveat, or question.
Reenu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: